Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

239 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A simple test for the diagnosis of absorptive, resorptive and renal hypercalciurias.
Pak CY, Kaplan R, Bone H, Townsend J, Waters O. Pak CY, et al. Among authors: bone h. N Engl J Med. 1975 Mar 6;292(10):497-500. doi: 10.1056/NEJM197503062921002. N Engl J Med. 1975. PMID: 163960
Diagnosis of hyperparathyroidism.
Bone HG 3rd, Snyder WH 3rd, Pak CY. Bone HG 3rd, et al. Annu Rev Med. 1977;28:111-7. doi: 10.1146/annurev.me.28.020177.000551. Annu Rev Med. 1977. PMID: 193430
Primary hyperparathyroidism must be considered in the differential diagnosis of hypercalcemia, nephrolithiasis, metabolic bone disease, and pancreatitis and peptic-ulcer disease. ...
Primary hyperparathyroidism must be considered in the differential diagnosis of hypercalcemia, nephrolithiasis, metabolic bone diseas …
The role of 1 alpha, 25-dihydroxyvitamin D in the mediation of intestinal hyperabsorption of calcium in primary hyperparathyroidism and absorptive hypercalciuria.
Kaplan RA, Haussler MR, Deftos LJ, Bone H, Pak CY. Kaplan RA, et al. Among authors: bone h. J Clin Invest. 1977 May;59(5):756-60. doi: 10.1172/JCI108696. J Clin Invest. 1977. PMID: 192763 Free PMC article.
Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism.
Silverberg SJ, Bone HG 3rd, Marriott TB, Locker FG, Thys-Jacobs S, Dziem G, Kaatz S, Sanguinetti EL, Bilezikian JP. Silverberg SJ, et al. Among authors: bone hg 3rd. N Engl J Med. 1997 Nov 20;337(21):1506-10. doi: 10.1056/NEJM199711203372104. N Engl J Med. 1997. PMID: 9366582 Clinical Trial.
Romosozumab in postmenopausal women with low bone mineral density.
McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG. McClung MR, et al. Among authors: bone hg. N Engl J Med. 2014 Jan 30;370(5):412-20. doi: 10.1056/NEJMoa1305224. Epub 2014 Jan 1. N Engl J Med. 2014. PMID: 24382002 Clinical Trial.
Romosozumab was also associated with large increases in bone mineral density at the total hip and femoral neck, as well as transitory increases in bone-formation markers and sustained decreases in a bone-resorption marker. ...CONCLUSIONS: In postmenopausal wo …
Romosozumab was also associated with large increases in bone mineral density at the total hip and femoral neck, as well as transitory …
Ten years' experience with alendronate for osteoporosis in postmenopausal women.
Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA; Alendronate Phase III Osteoporosis Treatment Study Group. Bone HG, et al. N Engl J Med. 2004 Mar 18;350(12):1189-99. doi: 10.1056/NEJMoa030897. N Engl J Med. 2004. PMID: 15028823 Clinical Trial.
RESULTS: Treatment with 10 mg of alendronate daily for 10 years produced mean increases in bone mineral density of 13.7 percent at the lumbar spine (95 percent confidence interval, 12.0 to 15.5 percent), 10.3 percent at the trochanter (95 percent confidence interval, 8.1 t …
RESULTS: Treatment with 10 mg of alendronate daily for 10 years produced mean increases in bone mineral density of 13.7 percent at th …
Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery.
Khan A, Bilezikian J, Bone H, Gurevich A, Lakatos P, Misiorowski W, Rozhinskaya L, Trotman ML, Tóth M. Khan A, et al. Among authors: bone h. Eur J Endocrinol. 2015 May;172(5):527-35. doi: 10.1530/EJE-14-0877. Epub 2015 Jan 30. Eur J Endocrinol. 2015. PMID: 25637076 Free PMC article. Clinical Trial.
Therapeutic controversies in primary hyperparathyroidism.
Silverberg SJ, Bilezikian JP, Bone HG, Talpos GB, Horwitz MJ, Stewart AF. Silverberg SJ, et al. Among authors: bone hg. J Clin Endocrinol Metab. 1999 Jul;84(7):2275-85. doi: 10.1210/jcem.84.7.5842-1. J Clin Endocrinol Metab. 1999. PMID: 10404790
Photon absorptiometric analysis of bone density in primary hyperparathyroidism.
Pak CY, Stewart A, Kaplan R, Bone H, Notz C, Browne R. Pak CY, et al. Among authors: bone h. Lancet. 1975 Jul 5;2(7923):7-8. doi: 10.1016/s0140-6736(75)92950-5. Lancet. 1975. PMID: 49647
Thus, most of the postmenopausal women with primary hyperparathyroidism had low bone density, whereas most men and premenopausal women with this condition had normal bone density. The results support the conclusion that oestrogen deficiency may contribute to the dev …
Thus, most of the postmenopausal women with primary hyperparathyroidism had low bone density, whereas most men and premenopausal wome …
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwiński E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S. Bone HG, et al. Lancet Diabetes Endocrinol. 2017 Jul;5(7):513-523. doi: 10.1016/S2213-8587(17)30138-9. Epub 2017 May 22. Lancet Diabetes Endocrinol. 2017. PMID: 28546097 Clinical Trial.
Secondary outcomes included new vertebral, hip, and non-vertebral fractures as well as bone mineral density (BMD) at the lumbar spine, total hip, femoral neck, and one-third radius. ...
Secondary outcomes included new vertebral, hip, and non-vertebral fractures as well as bone mineral density (BMD) at the lumbar spine …
239 results
Jump to page
Feedback